Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

Abstract

Background Fluticasone furoate/vilanterol trifenatate (FF/VI) is an inhaled therapy for the treatment of asthma, with a prolonged duration of anti-inflammatory and bronchodilatory action. This study investigated the global metabolomic and lipidomic profile following treatment with FF/VI or placebo and assessed whether changes correlated with exhaled nitric oxide levels as a measure of airway inflammation. Methods This was a single-center, randomized, double-blind, placebo-controlled, two-period, crossover, repeat-dose study. Adults with asthma (forced expiratory volume in 1 s ≥ 60% predicted; fraction of exhaled nitric oxide [FeNO] > 40 parts per billion) received once-daily FF/VI 100 µg/25 µg or placebo for 14 days, followed by a 21-day washout period. Serum samples were taken at pre-dose (T1), and 15 and 21 days (T2 and T3, respectively) post dose in each period. The metabolomic and lipidomic profiles were analyzed by liquid chromatography with tandem mass spectrometry and polar liquid chromatography platforms, and ions were matched to a library of standards for metabolite identification and quantification. FeNO values at each timepoint were evaluated for correlations with the biochemical data. Results Of 27 randomized participants (mean age 24.5 years, 63% male), 26 provided serum samples for metabolomic analysis. A total of 1969 metabolites were identified, 1634 of which corresponded to a named structure in a reference library. Treatment-related changes in the metabolome were generally subtle, with a modest increase in metabolite perturbations across timepoints. The percentage of metabolites with significant changes (p < 0.05 for all) (increases↑/decreases↓) versus placebo were: 2.1% (1.1%↑/1.0%↓), 6.7% (0.46%↑/6.2%↓) and 11.8% (0.86%↑/10.9%↓) at T1, T2 and T3, respectively. Treatment with FF/VI reduced FeNO levels by 60%, whereas the systemic intermediates involved in NO biosynthesis remained unaffected. Evidence of systemic anti-inflammatory activity was seen in complex lipid pathways, suggesting reduced phospholipase-A2 activity, but without downstream impact on free fatty acids or inflammatory mediators. Consistent with the pathogenesis of asthma, there was evidence of higher fatty acid β-oxidation and lower glycolysis in the placebo arm; this pattern was reversed in the treatment arm. Conclusions Despite the prolonged airway anti-inflammatory action of FF/VI, this was accompanied by only subtle systemic metabolomic and lipidomic changes. Trial registration Prospectively registered on ClinicalTrials.gov registry number NCT02712047

A steroid‐resistant cockroach allergen model is associated with lung and cecal microbiome changes

“…An initial attempt to examine how the microbiome changes alter the metabolite profile with PiCRUSt analysis, showed no significant effect in the low biomass environment of the lung, but significant changes in specific pathways in the gut microbiome of Flut‐treated animals. Interestingly, several the amino acid biosynthetic pathways were upregulated and is consistent with recent metabolite observations in asthma patients (Daley‐Yates et al, 2022 ; Durack et al, 2017 ). One pathway in particular, tyrosine metabolism, is often altered during inflammatory disease (Vacca et al, 2020 ; Zhao et al, 2022 ; Zheng, Parra‐Izquierdo, et al, 2022 ).…”

Serum Metabolomics Reveals Metabolomic Profile and Potential Biomarkers in Asthma

“… 47 A handful of studies have identified that abnormal mitochondrial β-oxidation contributed substantially to several aspects of asthma, including pathogenesis, disease severity, therapy response, etc. 32 48 49 Al-Khami et al . 50 showed that carnitine palmitoyltransferase 1 (CPT1), a key fatty acid oxidation enzyme, in lung was markedly upregulated in ovalbumin (OVA)-induced murine model of asthma.…”

Metabolomics in Animal Models of Bronchial Asthma and Its Translational Importance for Clinics

“…The authors revealed 22 different metabolites in the serum and 21 metabolites in the urine of budesonide + salbutamol treated asthmatic children compared with asthmatic children treated with a placebo, suggesting reprogramming in seven metabolic pathways: arginine and proline metabolism; taurine and hypotaurine metabolism; glycine, serine and threonine metabolism; glyoxylate and dicarboxylate metabolism; methane metabolism; citrate cycle; and pyruvate metabolism [ 175 ]. On the other hand, treatment of adult asthmatics with inhaled fluticasone furoate/vilanterol trifenatate was accompanied by only subtle systemic metabolomic and lipidomic changes [ 176 ].…”